Sign In
Buy NVRO
$5.84
+0 (+0%)
At Close: Jul 01, 2025
Nevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology
11:04am, Monday, 05'th Apr 2021
REDWOOD CITY, Calif., April 5, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss
09:56am, Thursday, 25'th Feb 2021
Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.
Nevro Corp (NVRO) CEO Keith Grossman on Q4 2020 Results - Earnings Call Transcript
10:04pm, Wednesday, 24'th Feb 2021
Nevro Corp (NVRO) CEO Keith Grossman on Q4 2020 Results - Earnings Call Transcript
Recap: Nevro Q4 Earnings
05:01pm, Wednesday, 24'th Feb 2021
Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which beat the
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
12:48pm, Tuesday, 12'th Jan 2021
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
08:17am, Tuesday, 29'th Dec 2020
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
04:08pm, Monday, 28'th Dec 2020
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
Nevro: More Opioid-Free Pain Relief
03:39am, Friday, 18'th Dec 2020
Nevro has been prospering in its chosen specialty of opioid-free pain relief. Nevro's Omnia launch has been dampened by the pandemic; expect good things as the pandemic moves to the rear.
Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California
06:54pm, Monday, 14'th Dec 2020
MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent
Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific
04:30pm, Monday, 14'th Dec 2020
REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2020 Results - Earnings Call Transcript
01:56pm, Sunday, 08'th Nov 2020
Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2020 Results - Earnings Call Transcript
Charting a successful technical test, S&P 500 nails the breakout point
04:35pm, Tuesday, 20'th Oct 2020
Technically speaking, the major U.S. benchmarks continue to digest an October breakout amid still bullish bigger-picture price action, writes Michael Ashbaugh.
Charting a bullish reversal, S&P 500 rallies from gap support
03:15pm, Friday, 16'th Oct 2020
U.S. stocks are firmly higher early Friday, rising after a strong batch of economic data. The early upturn punctuates a not-so-damaging mid-week pullback,...
Bull trend strengthens: S&P 500, Nasdaq clear 20-day volatility bands
04:54pm, Tuesday, 13'th Oct 2020
Technically speaking, the U.S. benchmarks’ bigger-picture backdrop has strengthened amid unseasonably constructive October price action, writes Michael...
